AstraZeneca Q4 Sales Rise 4% to $15.5B, Cancer Unit Up 11%
AstraZeneca reported fourth-quarter 2025 sales of $15.50 billion, up 4% year over year, and adjusted earnings of $2.12 per share. The cancer portfolio rose 11% to $7.03 billion on Tagrisso, Imfinzi and Calquence strength, underpinning mid-to-high single-digit revenue growth guidance for 2026.
1. Q4 2025 Financial Results
AstraZeneca delivered fourth-quarter revenues of $15.50 billion, a 4% increase year over year, and reported adjusted earnings of $2.12 per share, exceeding consensus estimates and demonstrating resilience in core operations.
2. Cancer Portfolio Growth
The oncology division accounted for 45% of total sales, rising 11% to $7.03 billion. Tagrisso sales climbed 12% to $1.90 billion, Imfinzi jumped 39% to $1.75 billion, and Calquence increased 20% to $967 million.
3. Other Segment Performance
Cardiovascular, renal and metabolism revenue fell 3% to $3.05 billion, with Farxiga at $2.06 billion, up 7%. Respiratory & Immunology sales grew 12% to $2.37 billion, while Rare Disease was flat at $2.37 billion amid a 16% rise in Ultomiris and a 26% drop in Soliris.
4. Regional Sales and 2026 Outlook
U.S. sales rose 6% to $6.93 billion and China sales increased 1% to $1.38 billion. The company forecasts mid-to-high single-digit revenue growth and low double-digit core EPS growth for fiscal 2026, driven by more than 20 Phase III trial readouts this year.